Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 14Carboplatin 12Magnetic Resonance Spectroscopy 11Specimen Handling 10Gemcitabine 10pembrolizumab 8Pemetrexed 8atezolizumab 7Paclitaxel 7Radiotherapy, Intensity-Modulated 5Platinum 5Nivolumab 5Immunoglobulin G 5Doxorubicin 5Docetaxel 5Disulfides 5Bevacizumab 5130-nm albumin-bound paclitaxel 51,2-diaminocyclohexaneplatinum II citrate 5Cetuximab 4Biopsy 4durvalumab 3Temozolomide 3Standard of Care 3Rituximab 3Drug Therapy 3Dexamethasone 3Cyclophosphamide 3(225)Ac-DOTA-c(RGDyK) 3venetoclax 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Vitamin B 12 × 30 days × Clear all
NCT05096663 2026-05-18

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

SWOG Cancer Research Network

Phase 2/3 Active not recruiting
82 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡